(Q37166201)

18 August 2017

1 reference

title

From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors (English)

1 reference

18 August 2017

0 references

0 references

1

Edward D Gomperts

1 reference

18 August 2017

Jan Astermark

2

1 reference

PubMed ID

18485996

18 August 2017

Alessandro Gringeri

series ordinal

3

1 reference

PubMed ID

18485996

18 August 2017

Jerome Teitel

series ordinal

4

1 reference

18 August 2017

1 February 2008

1 reference

18 August 2017

1 reference

18 August 2017

22 Suppl 1

1 reference

18 August 2017

S1-11

1 reference

Factor VIII inhibitors in mild and moderate-severity haemophilia A.

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Immune tolerance therapy for haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Inhibitors in haemophilia: clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Clinical significance of reported changes in pain severity

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Prevalence and outcome of intracranial haemorrhage in haemophiliacs--a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH).

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Intracranial haemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Prevalence and incidence of intracranial haemorrhage in a population of children with haemophilia. The Hemophilia Growth and Development Study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: a White Paper of the Perinatal Task Force of the Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Iliopsoas haemorrhage in patients with haemophilia: results from one centre

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Surgical excision of a giant pelvic pseudotumour in a patient with haemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Intracranial haemorrhage among a population of haemophilic patients in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Considerations in the evaluation of haemophilia patients for short-term prophylactic therapy: a paediatric and adult case study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

A retrospective postlicensure survey of FEIBA efficacy and safety.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Long‐term FEIBA prophylaxis does not prevent progression of existing joint disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Monitoring the bioavailability of FEIBA with a thrombin generation assay.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

Therapeutic decision-making in inhibitor patients

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2808%2970001-8

7 January 2021

10.1016/S0268-960X(08)70001-8

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18485996